Compare · DXR vs MDLN
DXR vs MDLN
Side-by-side comparison of Daxor Corporation (DXR) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXR and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $52.27B, about 1188.8x DXR ($44.0M).
- Over the past year, DXR is up 16.5% and MDLN is down 2.3% - DXR leads by 18.8 points.
- MDLN has been more active in the news (4 items in the past 4 weeks vs 1 for DXR).
- MDLN has more recent analyst coverage (25 ratings vs 0 for DXR).
- Company
- Daxor Corporation
- Medline Inc.
- Price
- $10.90+3.81%
- $39.80-3.23%
- Market cap
- $44.0M
- $52.27B
- 1M return
- +11.51%
- +7.36%
- 1Y return
- +16.45%
- -2.33%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NASDAQ
- IPO
- 2025
- News (4w)
- 1
- 4
- Recent ratings
- 0
- 25
Daxor Corporation
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Latest DXR
- Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
- Chief Financial Officer Michel Robert J was granted 12,000 units of Daxor Common Stock, increasing direct ownership by 57% to 33,050 units (SEC Form 4)
- Chief Executive Officer Feldschuh Michael Richard was granted 30,000 units of Daxor Common Stock, increasing direct ownership by 14% to 243,694 units (SEC Form 4)
- Chief Scientific Officer Feldschuh Jonathan Adam was granted 25,000 units of Daxor Common Stock, increasing direct ownership by 46% to 78,908 units (SEC Form 4)
- SEC Form 4 filed by Director Goudie Joy S.
- SEC Form 4 filed by Director Cremisi Henry D.
- SEC Form 4 filed by Director Feuer Edward
- SEC Form 4 filed by Director Desrosiers Caleb
- SEC Form 8-K filed by Daxor Corporation
- Amendment: SEC Form 40-8F-2/A filed by Daxor Corporation
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)